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Correlation between hyperinflation defined as an elevated RV/TLC 
ratio and body composition and cytokine profile in patients with 
chronic obstructive pulmonary disease
Korelacje pomiędzy rozdęciem miąższu płucnego mierzonego wskaźnikiem RV%TLC 
i składem ciała oraz profilem cytokinowym u chorych na przewlekłą obturacyjną 
chorobę płuc
The study was performed as the part of National Center for Research and Development project “Chronic obstructive pulmonary 
disease (COPD) — systemic disease, the biggest threat of XXI century” (NO. 13 0034 06/2009).
Abstract
Introduction: Body composition is an important prognostic factor in patients with COPD. The decrease in fat free mass (FFM), 
muscle mass (MM) and increase in visceral fat is associated with an elevated secretion of cytokines which promote systemic 
inflammation.
The aim of the study was to evaluate body composition and the cytokine profile in patients with COPD in relation with the pre-
sence of hyperinflation.
Material and methods: The study group consisted of 149 patients (61F, 88M) with stable COPD in all stages of severity aged 
68 ± 8.8 yrs. All the patients underwent spirometry and bodypletysmography with bronchial reversibility testing. Hyperinflation 
was defined as RV%TLC > 48% and > 126% predicted. Body composition was analyzed by bioimpedance. The following serum 
inflammatory markers were evaluated: C-reactive protein, IL-6, IL-8, TNF-a, CC16, adiponectin and resistin.
Results: Hyperinflation was found in 96 patients (group A) and it was more frequent in women than men (49/61 vs. 47/88, p < 0.001). 
BMI and age in this group were comparable to those in patients without hyperinflation (group B). Patients with hyperinflation have 
lover FFM, FFM index, MM and MM index and total body water and higher fat mass and fat mass index. We found significantly 
higher serum concentrations of inflammatory markers in group A: IL-6 – 6.4 ± 10.9 vs. 3.6 ± 4.2 pg/ml, resistin – 9.3 ± 4.2 vs. 
7.6 ± 2.4 ng/ml, CRP 4.1 ± 2.3 vs. 2.9±2.1 mg/l, respectively.
Conclusions: Patients with hyperinflation have a lower FFMI, TBW and MMI and a higher proportion of fat tissue. Hyperinflation 
is associated with elevated concentrations of inflammatory markers what may be associated with more severe disease. Body 
compositions abnormality and higher activity of systemic inflammation could therefore be a negative prognostic factor in COPD 
patients.
Key words: COPD, RV%TLC, body composition, systemic inflammation
Pneumonol Alergol Pol 2015; 83: 120–125
Streszczenie
Wstęp: Skład ciała jest ważnym czynnikiem prognostycznym u chorych na POChP. Spadek beztłuszczowej masy ciała (FFM), 
masy mięśni (MM) i wzrost masy trzewnej tkanki tłuszczowej jest związane ze wzrostem wydzielania cytokin odpowiedzialnych 
za systemowe zapalenie.
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Celem pracy była ocena wpływu hiperinflacji układu oddechowego na stan odżywienia i profilu cytokin u chorych na POChP.
Materiał i metody: Grupa badana składała się z 149 chorych (61K, 88M), w stabilnym okresie POChP, którzy reprezentowali 
wszystkie stopnie ciężkości choroby, w wieku 68 ± 8,8 lat. Wszyscy chorzy mieli wykonaną spirometrię i pletyzmografię z próbą 
rozkurczową. Rozdęcie było definiowane, jako zwiększenie RV%TLC > 48% and > 126% wn. Skład ciała był mierzony metodą 
bioimpendancji. Wykonano pomiar następujących cytokin w surowicy: białko C-reaktywne (CRP), IL-6, IL-8, TNF-a, CC16, adi-
ponektyna i rezystyna.
Wyniki: Rozdęcie stwierdzono u 96 chorych (grupa A), było ono częstsze u kobiet niż mężczyzn (49/61 v. 47/88, p < 0,001). 
Indeks masy ciała i wiek były podobne do grupy chorych bez rozdęcia (grupa B). Grupa A miała niższe FFM i FFMI, MM i MMI 
i całkowitą masę wody oraz wyższą masę tłuszczową i indeks masy tłuszczowej. W grupie A stwierdzono istotnie statystycznie 
wyższe stężenie w surowicy markerów zapalenia: IL-6 — 6,4 ± 10,9 v. 3,6 ± 4,2 pg/ml, resistin — 9,3 ± 4,2 v. 7,6 ± 2,4 ng/ml, 
CRP 4,1 ± 2,3 v. 2,9 ± 2,1 mg/l.
Wnioski: Chorzy, u których stwierdza się rozdęcie płuc mają niższe FFMI, TBW, MMI i więcej tkanki tłuszczowej. U chorych 
z rozdęciem płuc stwierdza się podwyższone stężenie markerów stanu zapalnego w porównaniu z chorymi bez rozdęcia, co może 
świadczyć o bardziej zaawansowanym procesie chorobowym. Zarówno zaburzenia w składzie ciała jak i wyższa aktywność 
zapalenia systemowego w grupie chorych z rozdęciem płuc może wskazywać na ich gorsze rokowanie
Słowa kluczowe: POChP, RV%TLC, skład ciała, zapalenie
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Introduction
Chronic obstructive pulmonary disease is 
characterized by progressive airflow limitation 
which is a result an inflammatory response in 
the airways to noxious particles and gases [1]. 
Pathological changes that lead to airway obstruc-
tion may have the form of chronic bronchitis 
and/or pulmonary emphysema. In patients with 
predominant chronic bronchitis the inflammatory 
process involves mainly the small airways and 
bronchioles, resulting in peribronchiolar fibrosis, 
muscular hypertrophy and mucus hypersecre-
tion. Whereas in patients with predominant em-
physema, pronounced lung parenchyma destruc-
tion is observed; the loss of lung elasticity impairs 
emptying of the lungs during expiration leading to 
an increase in the end-expiratory lung volume [2]. 
This process intensifies with increasing airway 
obstruction e.g. during COPD exacerbation. Irre-
spective of the predominant nature of pathologi-
cal changes, inflammatory cells cumulate in the 
airways, secreting various mediators responsible 
for the above mentioned process and structural 
changes [3]. Systemic inflammation results in the 
development of extrapulmonary manifestations, 
including alterations in body composition. In 
some patients cachexia occurs, in the majority, 
the loss of fat free mass (FFM) is observed along 
with the progression of the disease. Nutrition 
disorders are associated with increased secretion 
of inflammatory mediators (TNF-a, IL-6, IL-8, 
CRP) [4]. Low body mass index (BMI) is believed 
to be an independent risk factor of mortality in 
COPD [5]. Lung hyperinflation has an impact on 
numerous factors that are taken into account in 
the evaluation of the COPD patient including the 
sense of dyspnoea assessed by the Medical Re-
search Council (MRC) scale, quality of life, FEV1 
decline, energy balance and body composition 
disorders [6, 7].
The objective of the study was to evaluate the 
influence of lung hyperinflation on the nutrition 
status and cytokine profile in patients with COPD.
Material and methods
The study group included 149 patients with 
stable COPD (61 women and 88 men) aged 68 ± 
8.8 years. COPD was diagnosed in accordance 
with the GOLD 2010 recommendations [8]. The 
criterion for stable COPD was lack of exacerba-
tion for a period of at least 6 weeks prior to study 
inclusion. 
The study group was divided into two sub-
groups: A — patients with hyperinflation, and 
B — patients without hyperinflation with pre-
defined criteria as described below. 
All patients underwent anthropometric mea-
surements of height and body mass including: fat 
free mass (FFM, kg), muscle mass (MM, kg), total 
body water (TBW, kg), body fat content (BF, %). 
The measurements were performed under fasting 
condition in the morning. Body mass index (BMI), 
muscle mass (MMI) and fat free mass indices 
(FFMI) were calculated. Body composition was 
assessed using bioimpedance (Tanita T5896, 
TANITA Corporation of America, Inc, Arlington 
Heights, USA). Spirometry with bronchial re-
versibility testing (LungTest 1000, MES, Poland) 
according to the guidelines of the Polish Respira-
tory Society (Polskie Towarzystwo Chorób Płuc, 
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PTChP) [9], bodyplethysmography (BodyBox, 
Medisoft, Sorinnes, Belgium and Vmax 6200 
Autobox (SensorMedics, Yorba Linda, USA) 
were performed. Lung hyperinflation was de-
fined as the residual volume/total lung capacity 
ratio (RV%TLC) > 48% and residual volume 
(RV) > 126% of predicted value [10]. The study 
was approved by the Bioethical Committee of 
the Warsaw Medical University (KB/207/2008). 
Fasting venous blood samples were collect-
ed for the assessment of systemic inflammation: 
CRP, IL-6, IL-8, TNF-a, CCL16, adiponectin and 
resistin were evaluated (ELISA, R&D Systems 
Quantikinine, (Minneapolis, Minnesota United 
State).
Statistical analysis
Statistical analysis was performed with Sta-
tistica for Windows (StatSoft, Inc. version 10. 
www.statsoft.com). The values of variables with 
normal distribution were presented as mean ± 
standard deviation, the variables non-normal 
distribution were presented as median and in-
terquartile range. Distribution normality was 
assessed using the Shapiro-Wilk test. Depending 
on the nature of distribution of the examined 
variable, comparisons between the groups were 
made using Student’s t test or Wilcoxon test. 
To evaluate significance of correlation coefficient, 
Spearman correlation test was used. P < 0.05 was 
regarded statistically significant.
Results
Lung hyperinflation was found in 96 pa-
tients (49 women, 47 men). It was more frequent 
in the group of women — 49 (51%) vs. 47 (49%) 
p < 0.001. The age of patients from the two 
groups was comparable, the groups did not 
differ in BMI (27.5 ± 5.4 vs. 27.5 ± 4.8 kg/m2). 
Both groups differed in the results of lung 
function tests (Table 1). Patients with hyperin-
flation had a lower pre and post- bronchodilator 
FEV1. Pre-bronchodilator FVC was also lower, 
however there were no differences in post-bron-
chodilator FVC. 
In patients with hyperinflation, lower fat 
free body mass and muscle mass were found, but 
a higher body fat and body water content mea-
sured in kilograms.
The analysis of body composition showed 
statistically significant differences between the 
study groups (Table 2).
The analysis of inflammatory markers showed 
statistically higher concentrations of serum IL-6, 
resistin and CRP in patients with lung hyperin-
Table 1. Results of lung test in the studied groups
Hyperinflation (+)
Group A
Hyperinflation (−)
Group B
p
FEV1 (l)*  1.19± 0.42  1.88 ± 0.60 0.000
FEV1 (%pred)*  48.30 ± 14.71 69.10 ± 15.65 0.000
Increase of FEV1 (l) 0.16 ± 0.11 0.25 ± 0.18 0.0005
Increase of FEV1 (%pred) 6.41 ± 4.13 9.15 ± 6.30 0.0018
FVC (l)* 2.66 ± 0.76 3.55 ± 0.88 0.0000
FVC (%w.n.)*
FVC (%pred)
82.72 ± 15.17 99.58 ± 16.97 0.0000
Increase of FVC (l) 0.35 ± 0.26 0.32 ± 0.28 NS
Increase of FVC (%pred) 10.65 ± 7.38 9.17 ± 7.62 NS
TLC (l)* 7.1 ± 1.59 6.98 ± 1.36 NS
TLC (%w.n.)*
TLC (%pred)
128.92 ± 21.4 113.29 ± 17.29 0.0000
RV (l)* 4.30 ± 1.09 3.29 ± 0.71 0.0000
RV (%w.n.)*
RV (%pred)
195.54 ± 44.32 136.26 ± 23.45 0.0000
RV%TLC* 60.46 ± 6.27 47.44 ± 5.98 0.0000
RV%TLC (%w.n.)* 147.0 ± 15.0 114.0 ± 10.0 0.0000
*15 minutes after 400 µg salbutamol inhalation; FEV1 — forced expiratory volume in 1 second); FVC — forced vital capacity; RV — residual volume; TLC — total 
lung capacity
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Table 2. Body composition in patients with hyperinflations (group A) and without hyperinflations (group B)
Hyperinflation (+) group A Hyperinflation (−) Group B p
Total body water
(TBW. kg)
36.5 ± 8.0 40.9 ± 7.8 0.0006
Fat free mass
(FFM. kg)
49.4 ± 10.2 55.9 ± 10.7 0.0003
Fat free mass 18.2 ± 2.5 19.6 ± 2.46 0.002
Fat mass (kg) 32.5 ± 7.9 28.8 ± 8.1 0.008
Index 
FFMI (kg/m2)
12.3 ± 3.6 10.3 ± 3.6 0.002
Muscle mass (kg) 47.6 ± 10.6 52.4 ± 10.3 0.0005
Index MMI (kg/m2) 17.5 ± 2.8 18.7 ± 2.4 0.001
Basal metabolic rate (kcal) 1472.6 ± 300.7 1646.0 ± 313.3 0.001
Table 3. Correlations between body mass compositions and lung test results
Parameters R p
FEV1 (l)/FEV1 (%w.n.) − FFMI 0.46/0.23 0.0000/0.0055
FEV1 (lLl)/FEV1 (%w.n.) − TBW 0.56/0.20 0.0000/0.014
FEV1 (l)/FEV1 (%w.n.) − MMI 0.45/0.21 0.0000/0.011
FVC (l) – FFMI (kg/m2) 0.41 0.0000
FVC (l) − TBW (kg) 0.61 0.0000
FVC (lL) – MMI (kg/m2) 0.40 0.0001/0.0001
TLC (%w.n.) − FFMI (kg/m2) −0.42 0.0000
TLC (l)/TLC (%w.n.) − TBW (kg) 0.43/ −0.40 0.0000/0.0000
TLC (%w.n.) – MMI (kg/m2) −0.44 0.00000
 RV (%w.n.) – FFMI (kg/m2) −0.40 0.000001
RV (%w.n.) – TBW (kg) −0.32 0.0001
RV (%w.n.) – MMI (kg/m2) −0.41 0.00000
RV%TLC – FFMI (kg/m2) −0.34 0.000032
RV%TLC – TBW (kg) −0.35 0.000025
RV%TLC – MMI (kg/m2) −0.33 0.000075
All abbreviations in the text
flation. The serum concentrations of the selected 
inflammatory markers in both study groups are 
presented in Table 4.
In the whole group, statistically significant 
correlations between level of adiponectin, re-
sistin, TNF-a and CCL16 protein and spiromet-
ric and plethysmographic indices were shown. 
Correlations with the degree of hyperinflation 
measured with RV%TLC were shown only for 
adiponectin and CCL16 protein. 
Discussion
The obtained results have shown differences 
in body composition of COPD patients, depend-
ing on the presence lung hyperinflation defined 
as an elevated RV/TLC ratio. Guera et al., while 
comparing patients with emphysema and chron-
ic bronchitis, observed malnutrition defined as 
BMI < 18 kg/m2 more frequently in patients with 
emphysema, compared to patients with chronic 
Pneumonologia i Alergologia Polska 2015, vol. 83, no. 2, pages 120–125 
124 www.pneumonologia.viamedica.pl
Table 4. Serum concentrations of systemic inflammations markers
Group A Group B P
IL6 (pg/ml) 6.4 ± 10.9 3.6 ± 4.2 0.004
IL8 (pg/ml) 12.9 ± 19.5 14.5 ± 35.0 NS
Adiponectin (mg/ml) 1.2 ± 8.7 1.1 ± 6.82.8 NS
Resistin (ng/ml) 9.3 ± 4.2 7.6 ± 2.4 0.0081
TNF-a (pg/ml) 2.4 ± 2.6 2.1 ± 0.8 NS
CCL16 (ng/ml) 29.1 ± 16.7 31.6 ± 15.3 NS
CRP (mg/ml) 4.1 ± 2.3 2.9 ± 2.21 0.003
All abbreviations in the text
Table 5.  Correlations between lung test results and  
systemic inflammations markers
Adiponectin/FEV1 (l)* −0.3 < 0.0001
Adiponectin/FVC (l)* −0.34 < 0.0001
Adiponectin/TLC (l) −0.28 0.001
Adiponectin/RV%TLC* 0.24 0.004
Resistin/FEV1 (%w.n.)* −0.2 0.015
TNF-a/RV (l)* 0.26 0.002
CCL16/RV%TLC* 0.38 < 0.001
bronchitis and asthma, in whom BMI > 28 kg/m2 
was more frequent [11]. Kurosaki et al. showed 
that in patients with pulmonary emphysema 
diagnosed at chest CT, the severity of emphy-
sematous lesions correlated with muscle and fat 
mass [12]. Furthermore, in COPD patients, a larger 
area of abdominal fat measured at CT was shown 
in comparison with the control group. This area 
increased with the severity of COPD, and cor-
related positively with the degree of dyspnea. In 
patients with emphysema, a negative correlation 
of the degree of emphysema with waist circum-
ference, fat free body mass, body fat mass and 
subcutaneous fat area was shown [13]. We did 
not find differences in BMI between the groups. 
Patients with lung hyperinflation had a lower 
fat free body mass, muscle mass and body water 
and a higher proportional body fat content. The 
mean FEV1% in the group was < 50% predicted 
and was statistically lower, compared to the group 
without hyperinflation, in addition, in the group 
with hyperinflation, improvement in FEV1 after 
administration of salbutamol was smaller. The 
reversibility test was negative in both groups. In 
the study group, a negative correlation between 
the degree of hyperinflation and total body water 
and FFMI and MMI was shown, what confirms the 
presence of body composition disorders, particu-
larly in patients with emphysema. The disorders 
may be the effect of lower physical activity [14], 
higher energy expenditure and systemic inflam-
mation. The degree of hyperinflation and the 
values of FEV1 are independent factors that influ-
ence mortality [15]. Patients with hyperinflation 
measured with IC/TLC ratio < 0.25, in the study 
by Casanova et al. had 3.15 times higher mortality 
risk than patients with IC/TLC > 0.25 [16]. What 
is the role of systemic inflammation in the pro-
cess? Deterioration of functional parameters is 
related to increased inflammatory markers [3]. 
In the group with hyperinflation, patients with 
worse functional parameters had significantly 
higher serum levels of IL-6, resistin and CRP. 
The literature evaluates systemic inflammation 
in COPD in various aspects. Piehl-Aulin et al. 
showed an elevated level of high-sensitivity 
(hs)CRP in stable COPD patients, compared 
to the control group; in the same group, they 
observed an elevated concentration of IL-6 in 
patients in FEV1 < 50% predicted, and IL-8 
in patients with a severe stage of the disease. 
However, the authors did not show an elevated 
concentration of TNF-a, compared to the con-
trol group, or correlation of its level with the 
severity of the disease [17]. In another study, 
an increased level of TNF-a and IL-8 in COPD 
patients, compared to healthy smokers was not 
shown [18]. Whereas Pinto-Plata demonstrat-
ed that TNF-a and IL-6 levels increase with 
COPD severity of [19]. Engström et al. showed 
a negative correlation between concentration of 
CCL16 protein and the degree of hyperinflation 
measured with RV/TLC, whereas in patients 
with FEV1%FVC < 0.7, a negative correlation 
between CRP and FEV1, FVC, RV/TLC and DLCO 
was found [19]. Fat tissue is also the source of 
active substances that participate in systemic 
inflammation [20, 21]. 
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Adiponectin, which is secreted by fat tissue, 
has an anti-inflammatory effect. Its level decreas-
es in obese patients and increases with the degree 
of COPD progression [22]. In the study group, the 
level of adiponectin did not depend on the degree 
of hyperinflation. Another factor that is secreted 
by fat tissue is resistin [23]. Its main role is to 
maintain carbohydrate homeostasis. It was shown 
that resistin is related to obesity, type 2 diabetes, 
atherosclerosis and chronic inflammation [24]. 
Literature presents inconsistent data on the level 
of resistin in patients with obstructive diseases. 
Some authors have shown that the level of re-
sistin increases with the severity of the disease 
[25], however, others have not found differences 
in its concentration between COPD patients and 
the control group [26]. In our study group, the 
serum resistin in patients with hyperinflation 
was statistically higher, furthermore, resistin 
correlated weakly but significantly with FEV1 
(% pred.), which indirectly proves its relation to 
systemic inflammation in COPD patients. It seems 
practical to assess body composition and systemic 
inflammation in COPD patients, particularly in 
those with predominant emphysema. 
Conclusions
COPD patients with lung hyperinflation have 
had lower FFMI, TBW, MMI and more body fat.
In patients with lung hyperinflation, elevated 
levels of inflammatory markers was found, what 
may indicate a more advanced progression of 
the disease.
Body composition disorders and more active 
systemic inflammation in patients with lung hy-
perinflation may imply poor prognosis.
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